ASX:PAA

PharmAust (PAA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PAA Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 3.27 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 3.88%
Price Target: N/A

Stock Analysis

Get PharmAust alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About PharmAust Stock (ASX:PAA)

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

PAA Stock News Headlines

April 10, 2024 | msn.com

PharmAust inks approval from Macquarie University for Open-Label MND extension study

March 27, 2024 | finance.yahoo.com

We Think PharmAust (ASX:PAA) Can Afford To Drive Business Growth

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2024 | msn.com

Closing Bell: ASX a little lower after hosting a Big 4 bank midweek spank

March 14, 2024 | msn.com

PharmAust files groundbreaking MND/ALS clinical data with the FDA

March 13, 2024 | fool.com.au

If you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 now

February 28, 2024 | finance.yahoo.com

PharmAust advances monepantel for motor neurone disease towards FDA approval

February 28, 2024 | finanznachrichten.de

PharmAust Limited: PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 28, 2024 | msn.com

PharmAust’s MPL could offer MND/ALS sufferers up to 56.5 months additional life expectancy

February 28, 2024 | finance.yahoo.com

PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

February 21, 2024 | msn.com

PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS

February 16, 2024 | msn.com

FDA shows the way for accelerated approval of PharmAust’s monepantel in MND

February 14, 2024 | finance.yahoo.com

PharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week alone

February 14, 2024 | msn.com

PharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’

February 10, 2024 | morningstar.com

Plains All American Pipeline LP PAA

February 1, 2024 | markets.businessinsider.com

Plains All American Pipeline L.P.

January 30, 2024 | benzinga.com

Plains All American Stock (NASDAQ:PAA) Dividends: History, Yield and Dates

January 30, 2024 | msn.com

PharmAust gets ethics committee green light for open-label MND extension study

January 28, 2024 | msn.com

FDA offers PharmAust clear guidance for orphan drug designation approval

January 23, 2024 | morningstar.com

Plains All American Pipeline LP

January 16, 2024 | msn.com

PharmAust partners with US-based Berry Consultants for Phase 2/3 study

January 1, 2024 | msn.com

PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24

December 21, 2023 | msn.com

Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust

December 20, 2023 | msn.com

Santa (and ATO) delivers PharmAust $550k cash boost for Christmas

December 12, 2023 | msn.com

Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise

December 2, 2023 | au.finance.yahoo.com

PharmAust Limited (ECQ.F)

See More Headlines

Receive PAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmAust and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:PAA
CUSIP: N/A
CIK: N/A
Web: www.pharmaust.com
Phone: 61 8 6161 7412
Fax: N/A
Employees: 2,020
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,750,000.00
Net Margins: -177.28%
Pretax Margin: N/A
Return on Equity: -101.98%
Return on Assets: -31.99%

Debt

Debt-to-Equity Ratio: 26.97
Current Ratio: 4.55
Quick Ratio: 2.24

Sales & Book Value

Annual Sales: $3.71 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 10.50
Book Value: A$0.02 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 394,330,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.27

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Sam Michael Wright A.C.I.S. (Age 46)
ACIS, AFin, DipAcc, M.A.I.C.D., MAICD, Finance Director, Company Secretary & Non-Executive Director
Comp: $138k
Ms. Fiona Milner
General Manager of Epichem Pty Ltd
Dr. Michael Thurn Ph.D.
CEO & Director
Dr. Gary Pitt
Head of Chemistry
Dr. James Rixson
Head of Production

Key Competitors

View All Competitors

Insiders

This page (ASX:PAA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PharmAust (PAA) Stock Price, News & Analysis

About PharmAust Stock (ASX:PAA)

PAA Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info